These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 12634968)

  • 1. Whole-body FDG-PET in patients with stage I non-seminomatous germ cell tumours.
    Lassen U; Daugaard G; Eigtved A; Højgaard L; Damgaard K; Rørth M
    Eur J Nucl Med Mol Imaging; 2003 Mar; 30(3):396-402. PubMed ID: 12634968
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of (18)fluoro-2-deoxyglucose positron emission tomography in initial staging and re-staging after chemotherapy for testicular germ cell tumours.
    Spermon JR; De Geus-Oei LF; Kiemeney LA; Witjes JA; Oyen WJ
    BJU Int; 2002 Apr; 89(6):549-56. PubMed ID: 11942962
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [18F]-FDG-PET in clinical stage I/II non-seminomatous germ cell tumours: results of the German multicentre trial.
    de Wit M; Brenner W; Hartmann M; Kotzerke J; Hellwig D; Lehmann J; Franzius C; Kliesch S; Schlemmer M; Tatsch K; Heicappell R; Geworski L; Amthauer H; Dohmen BM; Schirrmeister H; Cremerius U; Bokemeyer C; Bares R
    Ann Oncol; 2008 Sep; 19(9):1619-23. PubMed ID: 18453520
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Positron emission tomography with [18 F]-2-fluoro-2-deoxy-D-glucose (18FDG-PET) in diagnosis of retroperitoneal lymph node metastases of testicular tumors].
    Müller-Mattheis V; Reinhardt M; Gerharz CD; Fürst G; Vosberg H; Müller-Gärtner HW; Ackermann R
    Urologe A; 1998 Nov; 37(6):609-20. PubMed ID: 9887489
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic accuracy of integrated (18)F-FDG PET/CT for restaging patients with malignant germ cell tumours.
    Sharma P; Jain TK; Parida GK; Karunanithi S; Patel C; Sharma A; Thulkar S; Julka PK; Bal C; Kumar R
    Br J Radiol; 2014 Aug; 87(1040):20140263. PubMed ID: 24896199
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Significance of 18F-FDG PET/CT in Characterization of Equivocal Lesions in High-Risk Testicular Carcinoma in Restaging Setting.
    Rasheed R; Al-Kandari F; Ghanem M; Marafi F; Usmani S
    Asian Pac J Cancer Prev; 2020 Feb; 21(2):511-515. PubMed ID: 32102532
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [18F]Fluorodeoxyglucose positron emission tomography in nonseminomatous germ cell tumors after chemotherapy: the German multicenter positron emission tomography study group.
    Oechsle K; Hartmann M; Brenner W; Venz S; Weissbach L; Franzius C; Kliesch S; Mueller S; Krege S; Heicappell R; Bares R; Bokemeyer C; de Wit M;
    J Clin Oncol; 2008 Dec; 26(36):5930-5. PubMed ID: 19018083
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic value of 18F-FDG positron emission tomography for detection and treatment control of malignant germ cell tumors.
    Tsatalpas P; Beuthien-Baumann B; Kropp J; Manseck A; Tiepolt C; Hakenberg OW; Burchert W; Franke WG; Wirth MP
    Urol Int; 2002; 68(3):157-63. PubMed ID: 11919460
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of 18F-FDG PET/CT in the management of testicular cancers.
    Cook GJ; Sohaib A; Huddart RA; Dearnaley DP; Horwich A; Chua S
    Nucl Med Commun; 2015 Jul; 36(7):702-8. PubMed ID: 25757201
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fluorodeoxyglucose PET in the initial staging of germ cell tumours.
    Hain SF; O'Doherty MJ; Timothy AR; Leslie MD; Partridge SE; Huddart RA
    Eur J Nucl Med; 2000 May; 27(5):590-4. PubMed ID: 10853816
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does positron emission tomography using 18-fluoro-2-deoxyglucose improve clinical staging of testicular cancer?--Results of a study in 50 patients.
    Cremerius U; Wildberger JE; Borchers H; Zimny M; Jakse G; Günther RW; Buell U
    Urology; 1999 Nov; 54(5):900-4. PubMed ID: 10565755
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Early prediction of treatment response to high-dose chemotherapy in patients with relapsed germ cell tumors using [18F]FDG-PET, CT or MRI, and tumor marker].
    Pfannenberg AC; Oechsle K; Kollmannsberger C; Dohmen BM; Bokemeyer C; Bares R; Vontheim R; Claussen CD
    Rofo; 2004 Jan; 176(1):76-84. PubMed ID: 14712410
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fluorodeoxyglucose positron emission tomography in the evaluation of germ cell tumours at relapse.
    Hain SF; O'Doherty MJ; Timothy AR; Leslie MD; Harper PG; Huddart RA
    Br J Cancer; 2000 Oct; 83(7):863-9. PubMed ID: 10970686
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of
    Dolci C; Ceppi L; Guerra L; Crivellaro C; Lamanna M; Adorni M; Elisei F; Bonazzi CM; Sina F; Fruscio R; Messa C
    Int J Gynecol Cancer; 2019 Oct; 29(8):1298-1303. PubMed ID: 31366569
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Fluorodeoxyglucose (FDO) positron emission tomography (PET) in testicular germ cell tumors in adults: preliminary French clinical evaluation, development of the technique and its clinical applications].
    Maszelin P; Lumbroso J; Theodore C; Foehrenbach H; Merlet P; Syrota A
    Prog Urol; 2000 Dec; 10(6):1190-9. PubMed ID: 11217558
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early prediction of treatment response to high-dose salvage chemotherapy in patients with relapsed germ cell cancer using [(18)F]FDG PET.
    Bokemeyer C; Kollmannsberger C; Oechsle K; Dohmen BM; Pfannenberg A; Claussen CD; Bares R; Kanz L
    Br J Cancer; 2002 Feb; 86(4):506-11. PubMed ID: 11870528
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Urologic treatment of testicular germ cell cancer].
    Fernández Gómez JM; Escaf Barmadah S; Guate Ortiz JL; Martín Huescar A; Fresno Forcelledo F; García Rodríguez J; Rodríguez Faba O; Jalón Monzón A; Rodríguez Martínez JJ
    Arch Esp Urol; 2002 Oct; 55(8):927-36. PubMed ID: 12455283
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Can we rely on PET in the follow-up of advanced seminoma patients?
    Siekiera J; Małkowski B; Jóźwicki W; Jasiński M; Wronczewski A; Pietrzak T; Chmielowska E; Petrus A; Kamecki K; Mikołajczak W; Kraśnicki K; Chłosta P; Drewa T
    Urol Int; 2012; 88(4):405-9. PubMed ID: 22507953
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic accuracy of 18F-FDG-PET in patients with testicular cancer: a meta-analysis.
    Zhao JY; Ma XL; Li YY; Zhang BL; Li MM; Ma XL; Liu L
    Asian Pac J Cancer Prev; 2014; 15(8):3525-31. PubMed ID: 24870751
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FDG PET is superior to CT in the prediction of viable tumour in post-chemotherapy seminoma residuals.
    Becherer A; De Santis M; Karanikas G; Szabó M; Bokemeyer C; Dohmen BM; Pont J; Dudczak R; Dittrich C; Kletter K
    Eur J Radiol; 2005 May; 54(2):284-8. PubMed ID: 15837411
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.